Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 10/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 10/20 | 0.40 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899543 | 0.99 | LTB4R (0.40) | PIN1LTB4RLTB4R2GSTP1CYP11B1 | |
| SCHEMBL6902570 | 0.76 | LTB4R (0.52) | LTB4RLTB4R2 | |
| SCHEMBL8569951 | 0.75 | PTGER1 (0.39) | LTB4RLTB4R2 | |
| SCHEMBL6898593 | 0.73 | ALOX5 (0.45) | KDM4ESMN1; SMN2KMT2A | |
| SCHEMBL6894310 | 0.72 | NR1H4 (0.44) | SMN1; SMN2KMT2A | |
| SCHEMBL6757535 | 0.70 | LTB4R (0.50) | LTB4RLTB4R2 | |
| SCHEMBL8843327 | 0.69 | LTB4R (0.40) | LTB4RLTB4R2GSTP1SMN1; SMN2 | |
| SCHEMBL9046839 | 0.69 | ALOX5 (0.46) | SMN1; SMN2KMT2A | |
| SCHEMBL8561280 | 0.68 | LTB4R (0.51) | LTB4RLTB4R2 | |
| SCHEMBL22305218 | 0.68 | MAOB (0.64) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673813-B2 | INHIBITING MEMBRANE TRANSPORT MEDIATED BY THE MULTIDRUG RESISTANCE ASSOCIATED PROTEIN MRP IN A PATIENT BY ADMINISTERING A COMPOUND HAVING AN AMPHIPHILIC ANION AND A MOLECULAR WEIGHT OF FROM 300 TO 950 DALTONS. | JEDLITSCHKY GABRIELE (DE) | 2004-01-06 | — | — | US | disclosed |
| US-20020013370-A1 | Methods for identifying and treating resistant tumors | SAWYER JASON SCOTT (US) | 2002-01-31 | — | — | US | disclosed |
| US-20020010213-A1 | Methods for identifying and treating resistant tumors | SAWYER JASON SCOTT (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1129707-A2 | Methods for identifying and treating resistant tumors | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2001-09-05 | — | — | EP | disclosed |
| US-6235785-B1 | DRUG RESISTANCE | ELI LILLY AND COMPANY | 2001-05-22 | — | — | US | disclosed |
| EP-0544488-B1 | Substituted phenyl phenol leukotriene antagonists | LILLY CO ELI (US) | 1998-03-11 | — | — | EP | disclosed |
| EP-0777472-A2 | METHODS FOR IDENTIFYING AND TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996036347-A1 | USE OF LEUKOTRIENE ANTAGONISTS FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-11-21 | — | — | WO | disclosed |
| EP-0743064-A1 | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease | ELI LILLY AND COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| US-5543428-A | ADMINISTERING SUBSTITUTED PHENOXYALKYL COMPOUNDS TO REVERSE DRUG RESISTANCE | ELI LILLY AND COMPANY (US) | 1996-08-06 | — | — | US | disclosed |
| WO-1996006604-A2 | METHODS FOR IDENTIFYING AND TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-03-07 | — | — | WO | disclosed |
| US-5462954-A | Antiinflammatory, antiallergens; treating asthma | ELI LILLY AND COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0544488-A2 | Substituted phenyl phenol leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013370-A1 | Methods for identifying and treating resistant tumors | ABCC1, SLC11A2, VHL | PIN1 1676/4885LTB4R 1827/4885LTB4R2 2396/4885 |
| US-20020010213-A1 | Methods for identifying and treating resistant tumors | ABCC1, SLC11A2, VHL | PIN1 1676/4885LTB4R 1827/4885LTB4R2 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.